RecruitingPhase 2Phase 3NCT06496997
A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome
Sponsor
Fayoum University
Enrollment
300 participants
Start Date
Aug 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the work is to compare the efficacy of equivalent doses of methylprednisolone, dexamethasone and hydrocortisone in patients with ARDS
Eligibility
Inclusion Criteria5
- We include patients receiving mechanical ventilation for hypoxemic respiratory failure if they met the diagnostic criteria for ARDS according to the American-European Consensus definition, as later reclassified on the basis of the 2012 Berlin criteria for the diagnosis of ARDS, defined as:
- Presence of acute hypoxemic respiratory failure (an arterial oxygen partial pressure to fraction of inspired oxygen ratio (PaO2/FiO2) of ≤ 300 mm Hg, requiring supplemental oxygen administrated by simple face mask, nasal cannula, or other similar oxygen-delivery device to maintain oxygen saturation at greater than 93% within the first 48 h of the onset of ARDS)
- Onset within 7 days of insult, or new (within 7 days) or worsening respiratory symptoms
- Bilateral opacities on chest x-ray or CT not fully explained by effusions, lobar or lung collapse, or nodules
- Cardiac failure not the primary cause of acute respiratory failure
Exclusion Criteria1
- We exclude patients with acute hypoxemic respiratory failure caused by congestive heart failure
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMethylprednisolone
Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)
DRUGDexamethasone
Dexamethasone at an equivalent dose of 13 mg/day
DRUGHydrocortisone
Hydrocortisone at an equivalent dose of 350 mg/day
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06496997
Related Trials
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT0670165636 locations
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT0670168236 locations
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
NCT0670166936 locations
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT0670307336 locations
Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)
NCT056000621 location